Lung cancer is the leading cause of cancer death among both men and women in the United States today, and a rising public health problem throughout the world. Although we?ve seen some improvement using combined modality approaches, these have had little impact on survival. Chemoprevention is a highly promising new approach that has already shown enormous potential for the control of other epithelial solid tumors. However, numerous studies of lung cancer chemoprevention have shown no benefit, and some have shown actual harmful effects in current smokers. It seems clear that previously unsuspected adverse interactions exist between tobacco carcinogens and chemopreventive agents. Although further studies of lung cancer chemoprevention are warranted, a thorough investigation of these carcinogen/chemoprevention interactions is necessary before further large-scale randomized trials are implemented. The overall goals of this translational, multidisciplinary Program project are to elucidate the interactions between tobacco carcinogens and chemopreventive agents, investigate the potential of celecoxib for lung cancer chemoprevention, and validate intermediate markers of lung carcinogenesis. To accomplish our goals, we propose to carry out a clinical chemoprevention trial in humans, while performing genetic, molecular, and pharmacologic studies to understand the carcinogenic process and the interaction of carcinogens with chemopreventive agents through the following projects: Project 1: Clinical Trial of Celecoxib in Lung Cancer Chemoprevention Project 2: Lung Cancer Prevention by COX-2 and 5-LOX Inhibitors, Retinoids, and Their Combinations Project 3: Molecular Alterations in Lung Carcinogenesis Project 4: The Role of Transcription Factor NF-kB in Lung Cancer Development and Chemoprevention Core components (Administration, Biostatistics and Data Management, Histology, and Pharmacology) are also included to provide the structure and expertise required for the successful integration and execution of these studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA091844-05
Application #
6949040
Study Section
Subcommittee G - Education (NCI)
Program Officer
Szabo, Eva
Project Start
2001-08-20
Project End
2008-07-31
Budget Start
2005-08-01
Budget End
2008-07-31
Support Year
5
Fiscal Year
2005
Total Cost
$1,728,827
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yang, Peiying; Cartwright, Carrie; Efuet, Ekem et al. (2014) Cellular location and expression of Na+, K+ -ATPase ? subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog 53:253-63
Gold, Kathryn A; Kim, Edward S; Liu, Diane D et al. (2014) Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res 20:1946-54
Gold, Kathryn A; Kim, Edward S; Wistuba, Ignacio I et al. (2013) Personalizing lung cancer prevention through a reverse migration strategy. Top Curr Chem 329:221-40
Lee, J Jack; Chu, Caleb T (2012) Bayesian clinical trials in action. Stat Med 31:2955-72
Gold, Kathryn A; Kim, Edward S; Lee, J Jack et al. (2011) The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) 4:962-72
Kim, Edward S; Hong, Waun K; Lee, J Jack et al. (2010) Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) 3:148-59
Behrens, Carmen; Feng, Lei; Kadara, Humam et al. (2010) Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res 16:34-44
Reuter, Simone; Prasad, Sahdeo; Phromnoi, Kanokkarn et al. (2010) Embelin suppresses osteoclastogenesis induced by receptor activator of NF-*B ligand and tumor cells in vitro through inhibition of the NF-*B cell signaling pathway. Mol Cancer Res 8:1425-36
Sandur, Santosh K; Pandey, Manoj K; Sung, Bokyung et al. (2010) 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol Cancer Res 8:107-18
Yadav, Vivek R; Prasad, Sahdeo; Kannappan, Ramaswamy et al. (2010) Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol 80:1021-32

Showing the most recent 10 out of 148 publications